标题
HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action
作者
关键词
-
出版物
Cancers
Volume 11, Issue 4, Pages 475
出版商
MDPI AG
发表日期
2019-04-04
DOI
10.3390/cancers11040475
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- HDAC11 regulates type I interferon signaling through defatty-acylation of SHMT2
- (2019) Ji Cao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells
- (2018) Bolun Wang et al. CELL CYCLE
- Crucial role of HO-1/IRF4-dependent apoptosis induced by panobinostat and lenalidomide in multiple myeloma
- (2018) Sishi Tang et al. EXPERIMENTAL CELL RESEARCH
- Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors
- (2018) Jooeun Bae et al. LEUKEMIA
- An Intramolecular Interaction of UHRF1 Reveals Dual Control for Its Histone Association
- (2018) Linfeng Gao et al. STRUCTURE
- EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial transcriptomic changes
- (2018) Taylor Harding et al. Oncotarget
- IMiDs through loss of Ikaros and Aiolos primes myeloma cells for daratumumab mediated killing by upregulation of CD38
- (2018) Pasquale L. Fedele et al. BLOOD
- HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications
- (2017) T Harada et al. LEUKEMIA
- Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma
- (2017) A Ray et al. LEUKEMIA
- EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma–Induced Epigenetic Suppression of Osteoblast Differentiation
- (2017) Juraj Adamik et al. MOLECULAR CANCER RESEARCH
- Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation
- (2017) John K. Simmons et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma
- (2017) Maria Angelica Stamato et al. Oncotarget
- VS-5584 mediates potent anti-myeloma activity via the upregulation of a class II tumor suppressor gene, RARRES3 and the activation of Bim
- (2017) Nurulhuda Mustafa et al. Oncotarget
- CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
- (2016) Inger S. Nijhof et al. BLOOD
- Increase of CIK cell efficacy by upregulating cell surface MICA and inhibition of NKG2D ligand shedding in multiple myeloma
- (2016) Chidimma A. Nwangwu et al. HEMATOLOGICAL ONCOLOGY
- Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma
- (2016) Nicola Amodio et al. MOLECULAR CANCER THERAPEUTICS
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma
- (2016) Teru Hideshima et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors
- (2016) Ariunzaya Bat-Erdene et al. Oncotarget
- The novel mechanism of lenalidomide activity
- (2015) E. C. Fink et al. BLOOD
- Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function
- (2015) Eva Sahakian et al. MOLECULAR IMMUNOLOGY
- Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation
- (2015) K.V. Woan et al. Molecular Oncology
- Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma
- (2015) T Hideshima et al. Blood Cancer Journal
- Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors
- (2014) Toshihiko Tashima et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma
- (2014) Sridurga Mithraprabhu et al. Epigenetics
- New and emerging HDAC inhibitors for cancer treatment
- (2014) Alison C. West et al. JOURNAL OF CLINICAL INVESTIGATION
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
- (2014) Jesús F San-Miguel et al. LANCET ONCOLOGY
- PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
- (2013) P. G. Richardson et al. BLOOD
- Histone deacetylase 10 promotes autophagy-mediated cell survival
- (2013) I. Oehme et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
- (2012) L. Santo et al. BLOOD
- Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?
- (2012) L. Neckers et al. CLINICAL CANCER RESEARCH
- Mutation of calcineurin subunit B M118 influences the activities of NF-AT and p53, but not calcineurin expression level
- (2011) Jinbo Cheng et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease
- (2011) S. D'Souza et al. BLOOD
- Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers
- (2011) Paul G. Richardson et al. BRITISH JOURNAL OF HAEMATOLOGY
- NFATc1 affects mouse splenic B cell function by controlling the calcineurin–NFAT signaling network
- (2011) Sankar Bhattacharyya et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma
- (2011) T. Hideshima et al. MOLECULAR CANCER THERAPEUTICS
- Identification of a Primary Target of Thalidomide Teratogenicity
- (2010) T. Ito et al. SCIENCE
- Epigenetics in cancer
- (2009) S. Sharma et al. CARCINOGENESIS
- The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance
- (2008) Alejandro Villagra et al. NATURE IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now